• Isoflavones are a class of phytoestrogens—plant-derived compounds with estrogenic activity. Soybeans and soy products are the richest sources of isoflavones in the human diet. (More information)
  • The results of randomized controlled trials suggest that substituting 50 g/day of soy protein for animal protein results in only a modest 3% reduction of LDL cholesterol. Isolated soy isoflavone supplements do not appear to have favorable effects on serum lipid profiles. (More information)
  • Consumption of soy isoflavones, at doses of <90 mg/day, may inhibit bone resorption and stimulate bone formation (More information)
  • Overall, the results of numerous observational studies do not support the idea that high soy isoflavone intakes in adults are protective against breast cancer. Limited research suggests that higher intakes of soy foods early in life may decrease the risk of breast cancer in adulthood. (More information)
  • Although scientists are interested in the potential for soy isoflavones to prevent or inhibit the progression of prostate cancer, evidence from observational studies that soy isoflavones are protective against prostate cancer is limited and inconsistent. (More information)
  • To date, studies on the effect of soy isoflavone consumption on menopausal symptoms have reported mixed results. (More information)
  • Some health effects of soy isoflavones may be dependent on whether or not the isoflavone metabolite, equol, is produced. (More information)
  • Although diets rich in soy or soy-containing products appear safe and potentially beneficial, the long-term safety of high doses of soy isoflavone supplements is not yet known. (More information)
  • At present, there is no convincing evidence that infants fed soy-based formula are at greater risk for adverse effects than infants fed cow’s milk-based formula. (More information)


Isoflavones are polyphenolic compounds that are capable of exerting estrogen-like effects. For this reason, they are classified as phytoestrogens—plant-derived compounds with estrogenic activity (1). Legumes, particularly soybeans, are the richest sources of isoflavones in the human diet. In soybeans, isoflavones are present as glycosides (bound to a sugar molecule). Fermentation or digestion of soybeans or soy products results in the release of the sugar molecule from the isoflavone glycoside, leaving an isoflavone aglycone. Soy isoflavone glycosides are called genistin, daidzin, and glycitin, while the aglycones are called genistein, daidzein, and glycitein (Figure 1). Unless otherwise indicated, quantities of isoflavones specified in this article refer to aglycones—not glycosides.

Figure 1. Chemical Structures of the Soy Isoflavone Aglycones: daidzein, genistein, and glycitein.

Metabolism and Bioavailability

The biological effects of soy isoflavones are strongly influenced by their metabolism, which is dependent on the activity of bacteria that colonize the human intestine (2). For example, the soy isoflavone daidzein may be metabolized in the intestine to equol, a metabolite that has greater estrogenic activity than daidzein, and to other metabolites that are less estrogenic. Studies that measure urinary equol excretion after soy consumption indicate that only about 33% of individuals from Western populations metabolize daidzein to equol (3). Thus, individual differences in the metabolism of isoflavones could have important implications for the biological activities of these phytoestrogens.

Biological Activities

Estrogenic and anti-estrogenic activities

Soy isoflavones are known to have weak estrogenic or hormone-like activity. Estrogens are signaling molecules that exert their effects by binding to estrogen receptors within cells (Figure 2). The estrogen-receptor complex interacts with DNA to change the expression of estrogen-responsive genes. Estrogen receptors are present in numerous tissues other than those associated with reproduction, including bone, liver, heart, and brain (4). Soy isoflavones and other phytoestrogens can bind to estrogen receptors, mimicking the effects of estrogen in some tissues and antagonizing (blocking) the effects of estrogen in others (5). Scientists are interested in the tissue-selective activities of phytoestrogens because anti-estrogenic effects in reproductive tissue could help reduce the risk of hormone-associated cancers (breast, uterine, and prostate), while estrogenic effects in other tissues could help maintain bone density and improve blood lipid profiles (cholesterol levels). The extent to which soy isoflavones exert estrogenic and anti-estrogenic effects in humans is currently the focus of considerable scientific research.

Figure 2. Chemical Structures of Some Endogenous Estrogens: 17 beta-estradiol, estriol, and estrione.

Estrogen receptor-independent activities

Soy isoflavones and their metabolites also have biological activities that are unrelated to their interactions with estrogen receptors (6). By inhibiting the synthesis and activity of certain enzymes involved in estrogen metabolism, soy isoflavones may alter the biological activity of endogenous estrogens and androgens (7-9). Soy isoflavones have also been found to inhibit tyrosine kinases (10), enzymes that play critical roles in the signaling pathways that stimulate cell proliferation. Additionally, isoflavones can act as antioxidants in vitro (11), but the extent to which they contribute to the antioxidant status of humans is not yet clear. Plasma F2-isoprostanes, biomarkers of lipid peroxidation in vivo, were significantly lower after two weeks of daily consumption of soy protein containing 56 mg of isoflavones than after consumption of soy protein providing only 2 mg of isoflavones (12). However, daily supplementation with 50-100 mg of isolated soy isoflavones did not significantly alter plasma or urinary F2-isoprostane levels (13, 14).

Disease Prevention

Cardiovascular disease

Serum cholesterol

Although controlled clinical trials conducted prior to 1995 suggested that substituting 25-50 g/day of soy protein for animal protein lowered serum LDL cholesterol by about 13% (15), more recent and better controlled trials indicate that the LDL cholesterol-lowering effect of soy protein is much more modest. A recent review of 22 randomized controlled trials concluded that substituting 50 g/day of soy protein for animal protein lowered LDL cholesterol by only about 3% (16). There is limited evidence that soy protein containing isoflavones is more effective than soy protein without isoflavones in lowering LDL cholesterol (17,18), but the consumption of soy isoflavones alone (as supplements or extracts) does not appear to have favorable effects on serum lipid profiles (16, 19-21). For more information on soy protein and cholesterol, see the article on Legumes.

Effects on arterial function

The preservation of normal arterial function plays an important role in cardiovascular disease prevention. The ability of arteries to dilate in response to nitric oxide produced by the endothelial cells that line their inner surface (endothelium-mediated vasodilation) is compromised in people at high risk for cardiovascular disease (22). To date, results of randomized controlled trials on the effect of soy isoflavones on arterial function have been mixed. However, most placebo-controlled trials found no significant improvement in endothelium-mediated vasodilation when postmenopausal women were supplemented with up to 80 mg/day of soy isoflavones (23-25) or up to 60 g/day of soy protein containing isoflavones (26-30). Arterial stiffness is another measure of arterial function. Measurements of arterial stiffness assess the distensibility of arteries, and a strong association between arterial stiffness and atherosclerosis has been observed (31). In placebo-controlled clinical trials, supplementation of postmenopausal women with 80 mg/day of a soy isoflavone extract for five weeks significantly decreased arterial stiffness (32), as did supplementation of men and postmenopausal women with 40 g/day of soy protein providing 118 mg/day of soy isoflavones for three months (29). Although most studies have not found supplementation with soy protein or isoflavones to improve endothelium-mediated vasodilation, preliminary research suggests that soy isoflavone supplementation may decrease arterial stiffness. However, a recent randomized controlled, cross-over trial in hypertensive individuals found that supplementation with soy protein containing 118 mg/day of isoflavones for six months did not improve measures of arterial function, including arterial stiffness (33). More research is needed to determine whether supplementation with soy isoflavones improves arterial function.

Hormone-associated cancers

Breast cancer

Breast cancer incidence in Asia, where average isoflavone intakes from soy foods range from 25-50 mg/day (34), is lower than breast cancer rates in the Western countries where average isoflavone intakes in non-Asian women are less than 2 mg/day (35, 36). However, many other hereditary and lifestyle factors could contribute to this difference. Epidemiological studies of dietary soy and breast cancer have reported conflicting results (see the article on Legumes). A few studies suggest that a higher soy intake during adolescence may lower risk of developing breast cancer later in life (37, 38). At present, there is little evidence that taking soy isoflavone supplements decreases risk of breast cancer. See the article on Legumes for more information about soy consumption and breast cancer risk.

Endometrial cancer

Because the development of endometrial (uterine) cancer is related to prolonged exposure to unopposed estrogens (estrogen not counterbalanced with the hormone progesterone), it has been suggested that high intakes of phytoestrogens with anti-estrogenic activity could be protective against endometrial cancer (39). In support of this idea, three retrospective case-control studies found that women with endometrial cancer had lower intakes of soy isoflavones from foods compared to cancer-free control groups (39-41). However, supplementation of postmenopausal women with soy protein providing 120 mg/day of isoflavones for six months did not prevent endometrial hyperplasia induced by the administration of exogenous estradiol (42). Although limited evidence from case-control studies suggests an inverse relationship between consumption of soy foods and endometrial cancer, there is no evidence from intervention trials that taking soy isoflavone supplements decreases endometrial cancer risk.

Prostate cancer

Mortality from prostate cancer is much higher in the US than in Asian countries, such as Japan and China (43). However, epidemiological studies do not provide consistent evidence that high intakes of soy foods are associated with reduced prostate cancer risk. See the article on Legumes for more information about soy foods and prostate cancer risk. The results of cell culture and animal studies suggest a potential role for soy isoflavones in limiting the progression of prostate cancer (44). Although soy isoflavone supplementation for up to one year did not significantly decrease serum concentration of prostate specific antigen (PSA) in men without confirmed prostate cancer (45-47), soy isoflavone supplementation appeared to slow the rising serum PSA concentration associated with prostate tumor growth in two small studies of prostate cancer patients (48, 49). One small, short-term (<1 month) study in prostate cancer patients found that men randomized to receive a high-phytoestrogen diet experienced a statistically significant improvement in PSA concentrations compared to men randomized to receive a low-phytoestrogen diet (50). A trial of soy milk supplementation (141 mg/day isoflavones) in men with PSA recurrent prostate cancer found that PSA levels increased by an average of 20% over a 12-month period compared to a 56% yearly increase prior to the study (51). A review published in 2006 found that isoflavone supplementation in prostate cancer patients favorably affected PSA concentrations in four out of eight trials (52). Additionally, a recent meta-analysis of eight studies found that isoflavones consumption was associated with a reduction in risk of prostate cancer, but the association was not statistically significant (53). Although such preliminary findings are encouraging, the results of larger randomized controlled trials, which are currently ongoing, are needed to determine whether soy isoflavone supplementation can play a role in the prevention or treatment of prostate cancer (54).


Although hip fracture rates are generally lower among Asian populations consuming soy foods than among Western populations, it is not yet clear whether increasing soy isoflavone consumption in Western populations helps to prevent osteoporosis (55). The results of short-term clinical trials (six months or less) assessing the effects of increased soy intake on biochemical markers of bone formation and bone resorption are inconsistent. Some controlled trials in postmenopausal women have found that increasing intakes of soy foods, soy protein, or soy isoflavones improves markers of bone resorption and formation (56-59) or attenuates bone loss (59, 60), but other trials have found no significant benefit of increasing soy intake (61-64). Randomized controlled trials of longer duration are required to determine whether increased soy intake can actually prevent losses in bone mineral density (BMD) or osteoporotic fracture. Two controlled clinical trials found that BMD losses over six months were significantly lower in postmenopausal women supplemented with soy protein containing isoflavones than in those supplemented with equal amounts of milk protein (62, 65), but two longer trials found that BMD loss did not significantly differ between postmenopausal women supplemented with soy protein containing isoflavones and those supplemented with milk protein (66, 67). A two-year clinical trial found that daily consumption of soy milk containing isoflavones significantly decreased BMD loss in the lumbar spine compared to daily consumption of soymilk without isoflavones (68), but three other studies found that BMD loss did not significantly differ between postmenopausal women taking soy protein supplements containing isoflavones and those taking soy protein supplements without or with negligible amounts of isoflavones (68-71). Loss of bone mineral content at the hip over one year was lower in Taiwanese women who took 80 mg/day of isolated soy isoflavones compared to placebo, but the difference was significant only in those women who were at least four years past menopause, had lower body weights, or had lower calcium intakes (72). Another study in Taiwanese women found that those taking 100 mg/day of isolated soy isoflavones for one year experienced less bone loss compared to the control group, but women taking 200 mg/day of supplemental isoflavones did not experience any benefit (73). Yet, a randomized controlled trial in European postmenopausal women found that supplementation with isoflavone-enriched foods (110 mg/day of isoflavones) for one year had no significant effect on BMD (74). A recent placebo-controlled trial in postmenopausal women, aged >60 years, found that neither supplemental soy protein (18 g/day) nor isoflavones (105 mg/day), alone or in combination, significantly affected BMD over a one-year period (75). To date, results of studies are conflicting, but a recent meta-analysis of nine randomized controlled trials (trial duration, one to 12 months) concluded that soy isoflavones, at doses of <90 mg/day, inhibit bone resorption and stimulate bone formation (76). Some authors have proposed that the effect of soy isoflavones on bone health may be dependent on whether or not the individual produces the isoflavones metabolite, equol (see Metabolism and Bioavailability) (77-80). This could possibly explain disparate results among clinical trials. Thus, while there is some evidence that isoflavone-rich diets have bone-sparing effects, it is not known whether increasing soy isoflavone intake appreciably decreases the risk of osteoporosis or osteoporotic fracture.

Cognitive decline

Scientific research on the effect of soy isoflavones on cognitive function is limited. An observational study that examined the relationship between soy intake and cognitive function found that Hawaiian men who reported consuming tofu at least twice weekly during midlife were more likely to have poor cognitive test scores 20-25 years later than those who reported consuming tofu less than twice a week (81). In an Indonesian study of elderly men and women, consumption of tofu was associated with worse memory, while consumption of tempe was associated with improved memory (82). In contrast, the results of several small clinical trials in postmenopausal women suggest that increasing soy isoflavone intake may result in modest improvements in performance on some cognitive tests for up to six months. Postmenopausal women given soy extracts, providing 60 mg/day of soy isoflavones for 6-12 weeks, performed better on cognitive tests of picture recall (short-term memory), learning rule reversals (mental flexibility), and a planning task compared to women given a placebo (83, 84). In a longer trial, postmenopausal women given supplements that provided 110 mg/day of soy isoflavones for six months performed better on a test of verbal fluency than women given placebos (85). In a cross-over trial lasting six months, women receiving 60 mg/day of soy isoflavones experienced significant improvements in cognitive performance and overall mood compared to when the women were given a placebo (86). However, in larger placebo-controlled trials, postmenopausal women receiving 80 mg/day of isoflavones for six months or 99 mg/day of isoflavones for one year did not affect performance on a battery of cognitive function tests, including tests for memory, attention, verbal fluency, motor control, and dementia (67, 87). A recent review of eight trials, seven of which were conducted in postmenopausal women, found half reported that soy isoflavone treatment was associated with improvements in cognitive function (88).

Disease Treatment

Menopausal symptoms

Hot flushes (flashes) are the primary reason that women seek medical attention for menopausal symptoms (89). Concern over potential adverse effects of hormone replacement therapy (90, 91) has led to increased interest in the use of phytoestrogen supplements by women experiencing menopausal symptoms (92). The effects of increasing soy isoflavone intake on the frequency of hot flushes have been examined in a number of randomized controlled trials (93-95). To date, at least four reviews of such trials have been published. A review published in 2002 found that only one out of eight randomized controlled trials of soy foods reported a significant reduction in the frequency of hot flushes, while three out of five controlled trials of soy isoflavone extracts reported a significant reduction in hot flush frequency (96). In general, any reductions observed were modest (10%-20%) compared to placebo. A 2004 systematic review that examined ten randomized controlled trials found that only four trials reported beneficial effects of soy preparations in the treatment of menopausal symptoms like hot flushes (95). More recently, another systematic review and meta-analysis of 12 randomized controlled trials found that soy isoflavone supplementation was associated with a small reduction in the number of hot flushes; this analysis found that women with a higher number of daily flushes experienced the greatest benefit from isoflavone therapy (94). One review that analyzed various trials according to the specific isoflavones contained in the supplements found that use of supplements containing primarily genistein reduced symptoms of hot flushes (97). Interestingly, a recent study found that only women who produced the isoflavone metabolite, equol (see Metabolism and Bioavailability), which was detected in the urine, experienced improvements in menopausal symptoms like hot flushes following soy isoflavone supplementation (98). Breast cancer survivors in particular may experience more frequent and severe hot flushes related to therapies aimed at preventing breast cancer recurrence (99). However, none of the randomized controlled trials in breast cancer survivors found that soy isoflavone supplementation was significantly more effective than a placebo in decreasing the frequency or severity of hot flushes (100-103). To date, studies on the effect of soy isoflavone consumption on menopausal symptoms have reported mixed results.


Food sources

Isoflavones are found in small amounts in a number of legumes, grains, and vegetables, but soybeans are by far the most concentrated source of isoflavones in the human diet (104, 105). Recent surveys suggest that average dietary isoflavone intakes in Japan, China, and other Asian countries range from 25-50 mg/day (34). Dietary isoflavone intakes are considerably lower in Western countries, where studies have found average isoflavone intakes to be as low as 2 mg/day (35, 36). Traditional Asian foods made from soybeans include tofu, tempeh, miso, and natto. Edamame refers to varieties of soybeans that are harvested and eaten in their green phase. Soy products that are gaining popularity in Western countries include soy-based meat substitutes, soy milk, soy cheese, and soy yogurt. The isoflavone content of a soy protein isolate depends on the method used to isolate it. Soy protein isolates prepared by an ethanol wash process generally lose most of their associated isoflavones, while those prepared by aqueous wash processes tend to retain them (106). Some foods that are rich in soy isoflavones are listed in Table 1, along with their isoflavone content (107). Because the isoflavone content of soy foods can vary considerably between brands and between different lots of the same brand (106), these values should be viewed only as a guide. Given the potential health implications of diets rich in soy isoflavones, accurate and consistent labeling of the soy isoflavone content of soy foods is needed. More information on the isoflavone content of foods is available from the USDA nutrient data laboratory.

Table 1. Total Isoflavone, Daidzein and Genistein Aglycone Content of Selected Foods* (107)
Food Serving Total Isoflavones (mg) Daidzein (mg) Genistein (mg)
Soy protein concentrate, aqueous washed 3.5 oz 102 43 56
Soy protein concentrate, alcohol washed 3.5 oz 12 7 5
Miso ½ cup 59 22 34
Soybeans, boiled ½ cup 47 23 24
Tempeh 3 ounces 37 15 21
Soybeans, dry roasted 1 ounce 37 15 19
Soy milk 1 cup 30 12 17
Tofu yogurt ½ cup 21 7 12
Tofu 3 ounces 20 8 12
Meatless (soy) hot dog 1 hot dog 11 3 6
Meatless (soy) sausage 3 links 3 0.6 2
Soy cheese, mozzarella 1 oz 2 0.3 1
*Isoflavone content of soy foods can vary considerably between brands and between different lots of the same brand (106); therefore, these values should be viewed only as a guide.


Soy isoflavone extracts and supplements are available as dietary supplements without a prescription in the US. These products are not standardized, and the amounts of soy isoflavones they provide may vary considerably. Moreover, quality control may be an issue with some of these products (108). When isoflavone supplements available in the US were tested for their isoflavone content by an independent laboratory, the isoflavone content in the product differed by more than 10% from the amount claimed on the label in approximately 50% of the products tested (109).

Infant formulas

Soy-based infant formulas are made from soy protein isolate and contain significant amounts of soy isoflavones. In 1997, the total isoflavone content of soy-based infant formulas that were commercially available in the US ranged from 32-47 mg/liter (~34 fluid ounces) (110).

Table 2. Total Isoflavone, Daidzein, and Genistein Aglycone Content of Selected Soy-based Infant Formulas
Soy-based Formula Serving Total Isoflavones (mg) Daidzein (mg) Genistein (mg)
Mead Johnson Prosobee, ready to feed 8 fl oz. 9.4 4.1 5.3
Ross Isomil, ready to feed 8 fl oz. 10.2 4.7 5.5
Wyeth-Ayerst Nursoy, ready to feed 8 fl oz. 6.4 1.8 3.9


Soy isoflavones have been consumed by humans as part of soy-based diets for many years without any evidence of adverse effects (105). The 75th percentile of dietary isoflavone intake has been reported to be as high as 65 mg/day in some Asian populations (111). Although diets rich in soy or soy-containing products appear safe and potentially beneficial, the long-term safety of very high supplemental doses of soy isoflavones is not yet known. One study in older men and women found that 100 mg/day of soy isoflavones for six months was well tolerated (112). Yet, long-term studies are needed to evaluate the safety of isoflavones.

Adverse effects

Safety for breast cancer survivors

The safety of high intakes of soy isoflavones and other phytoestrogens for breast cancer survivors is an area of considerable debate among scientists and clinicians (99, 113). The effects of high intakes of soy isoflavones on breast cancer recurrence and survival of breast cancer patients have not been well studied. The results of cell culture and animal studies are conflicting, but some have found that soy isoflavones can stimulate the growth of estrogen receptor positive (ER+) breast cancer cells (114, 115). High intakes of the soy isoflavone, genistein, interfered with the ability of tamoxifen to inhibit the growth of ER+ breast cancer cells implanted in mice (116), but it is not known if a similar effect would be seen in humans. A recent prospective study in 5,042 female breast cancer survivors in China, who were followed for a median of 3.9 years, found that consumption of isoflavone-rich soy foods was significantly associated with a 29% lower risk of death and a 32% lower risk of cancer recurrence (117). In this study, soy isoflavone consumption was associated with a nonsignificant, 21% reduction in risk of death and a significant, 23% reduction in risk of cancer recurrence (117). Very limited data from clinical trials suggest that increased consumption of soy isoflavones (38-45 mg/day) can have estrogenic effects in human breast tissue (118, 119). However, a study in women with biopsy-confirmed breast cancer found that supplementation with 200 mg/day of soy isoflavones did not increase tumor growth over the next 2-6 weeks before surgery when compared to a control group that did not take soy isoflavones (120). Given the available data, some experts think that women with a history of breast cancer, particularly ER+ breast cancer, should not increase their consumption of phytoestrogens, including soy isoflavones (99). However, other experts argue that there is not enough evidence to discourage breast cancer survivors from consuming soy foods in moderation (113), and the recent study mentioned above (117) indicates that moderate consumption of soy foods (11 g/day of soy protein) may even be beneficial to breast cancer survivors. Due to conflicting results, more research is needed to determine the safety of high soy isoflavone intake in breast cancer survivors.

Soy-based infant formulas

Infant formula made from soy protein isolate has been commercially available since the mid-1960s (121). As much as 25% of the infant formula sold in the US is soy-based formula (122). Since infants fed soy-based formulas are exposed to relatively high levels of isoflavones, which they can absorb and metabolize, concern has been raised regarding potential long-term effects on growth, development, as well as reproductive and immune function (110, 123). The results of at least six clinical trials comparing infants fed soy-based formula with infants fed cow’s milk-based formula indicate that soy-based formula supports normal growth and development in the first year of life (124). A prospective study evaluating growth and development in children fed breast milk, cow's milk-based formula, or soy-based formula is currently under way at the Arkansas Children's Nutrition Center. After five years into the study, adverse effects of soy formula have not been observed, and no differences in growth and development among the various groups have been noted (125). In addition, one retrospective study of 811 men and women at 20-34 years of age found no differences in height, weight, time of puberty, general health, or pregnancy outcomes between those fed soy-based formula as infants and those fed cow’s milk-based formula, although women fed soy-based formula reported significantly greater use of asthma or allergy drugs than women fed cow’s milk formula (126). The American Academy of Pediatrics recently published a report that reviews the indications and contraindications for the use of soy-based formulas (122). At present, there is no convincing evidence that infants fed soy-based formula are at greater risk for adverse effects than infants fed cow’s milk-based formula. However, long-term studies on the growth and development of infants fed soy-based formulas are currently ongoing (127, 128).

Thyroid function

In cell culture and animal studies, soy isoflavones have been found to inhibit the activity of thyroid peroxidase, an enzyme required for thyroid hormone synthesis (129, 130). However, high intakes of soy isoflavones do not appear to increase the risk of hypothyroidism as long as dietary iodine consumption is adequate (131). Since the addition of iodine to soy-based formulas in the 1960s, there have been no further reports of hypothyroidism in soy formula-fed infants (132). Several clinical trials, mostly in premenopausal and postmenopausal women with sufficient iodine intakes, have not found increased consumption of soy isoflavones to result in clinically significant changes in circulating thyroid hormone levels (133-137).


To date, studies have not examined the effect of an isoflavone-rich diet on fetal development or pregnancy outcomes in humans, and the safety of isoflavone supplements during pregnancy has not been established.

Drug interactions

Because colonic bacteria play an important role in the metabolism of soy isoflavones, antibiotic therapy could decrease their biological activity (138). Some evidence from animal studies suggests that high intakes of soy isoflavones, particularly genistein, can interfere with the antitumor effects of tamoxifen (Nolvadex) (116). Until more is known about potential interactions in humans, those taking tamoxifen or other selective estrogen receptor modulators (SERMs) to treat or prevent breast cancer should avoid soy protein supplements or isoflavone extracts (see Safety for breast cancer survivors). High intakes of soy protein may interfere with the efficacy of the anticoagulant medication warfarin. There is one case report of an individual on warfarin who developed subtherapeutic INR (prothrombin time) values upon consuming ~16 ounces of soy milk daily for four weeks (139). INR values returned to therapeutic levels two weeks after discontinuing soy milk. The amount of levothyroxine required for adequate thyroid hormone replacement has been found to increase in infants with congenital hypothyroidism fed soy formula (132, 140). Taking levothyroxine at the same time as a soy protein supplement also increased the levothyroxine dose required for adequate thyroid hormone replacement in an adult with hypothyroidism (141).

Authors and Reviewers

Originally written in 2004 by:
Jane Higdon, Ph.D.
Linus Pauling Institute
Oregon State University

Updated in January 2006 by:
Jane Higdon, Ph.D.
Linus Pauling Institute
Oregon State University

Updated in December 2009 by:
Victoria J. Drake, Ph.D.
Linus Pauling Institute
Oregon State University

Reviewed in December 2009 by:
Alison M. Duncan, Ph.D., R.D.
Associate Professor
Department of Human Health and Nutritional Sciences
University of Guelph
Guelph, Ontario, Canada

Copyright 2004-2015  Linus Pauling Institute


1.  Lampe JW. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr. 2003;133 Suppl 3:956S-964S.  (PubMed)

2.  Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr. 2003;89 Suppl 1:S45-58.  (PubMed)

3.  Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132(12):3577-3584.  (PubMed)

4.  National Cancer Institute. Understanding Estrogen Receptors/SERMs. National Cancer Institute. January, 2005.

5.  Wang LQ. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;777(1-2):289-309.  (PubMed)

6.  Barnes S, Boersma B, Patel R, et al. Isoflavonoids and chronic disease: mechanisms of action. Biofactors. 2000;12(1-4):209-215.  (PubMed)

7.  Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Perspect. 1998;106(2):85-92.  (PubMed)

8.  Whitehead SA, Cross JE, Burden C, Lacey M. Acute and chronic effects of genistein, tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells. Hum Reprod. 2002;17(3):589-594.  (PubMed)

9.  Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol. 2005;15(1):17-22.  (PubMed)

10.  Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262(12):5592-5595.  (PubMed)

11.  Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res. 1997;26(1):63-70.  (PubMed)

12.  Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr. 2000;72(2):395-400.  (PubMed)

13.  Hodgson JM, Puddey IB, Croft KD, Mori TA, Rivera J, Beilin LJ. Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis. 1999;145(1):167-172.  (PubMed)

14.  Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O. Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett. 2001;172(1):1-6.  (PubMed)

15.  Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333(5):276-282.  (PubMed)

16.  Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113(7):1034-1044.  (PubMed)

17.  Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005;81(2):397-408.  (PubMed)

18.  Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr. 2004;134(9):2395-2400.  (PubMed)

19.  Lichtenstein AH, Jalbert SM, Adlercreutz H, et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2002;22(11):1852-1858.  (PubMed)

20.  Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr. 2003;57(8):940-946.  (PubMed)

21.  Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006;91(3):772-780.  (PubMed)

22.  Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(21 Suppl 1):II27-33.  (PubMed)

23.  Squadrito F, Altavilla D, Crisafulli A, et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med. 2003;114(6):470-476.  (PubMed)

24.  Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol. 2000;85(11):1297-1301.  (PubMed)

25.  Katz DL, Evans MA, Njike VY, et al. Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric. 2007;10(6):500-507.  (PubMed)

26.  Kreijkamp-Kaspers S, Kok L, Bots ML, Grobbee DE, Lampe JW, van der Schouw YT. Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr. 2005;81(1):189-195.  (PubMed)

27.  Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ. Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. Am J Clin Nutr. 2003;78(1):123-130.  (PubMed)

28.  Blum A, Lang N, Vigder F, et al. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin Invest Med. 2003;26(1):20-26.  (PubMed)

29.  Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab. 2001;86(7):3053-3060.  (PubMed)

30.  Evans M, Njike VY, Hoxley M, Pearson M, Katz DL. Effect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal women. Menopause. 2007;14(1):141-149.  (PubMed)

31.  van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001;32(2):454-460.  (PubMed)

32.  Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol. 1997;17(12):3392-3398.  (PubMed)

33.  Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP. Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive subjects. J Am Coll Nutr. 2006;25(6):533-540.  (PubMed)

34.  Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 2006;55(1):1-12.  (PubMed)

35.  van Erp-Baart MA, Brants HA, Kiely M, et al. Isoflavone intake in four different European countries: the VENUS approach. Br J Nutr. 2003;89 Suppl 1:S25-30.  (PubMed)

36.  de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study(1-4). J Nutr. 2001;131(6):1826-1832.  (PubMed)

37.  Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev. 2001;10(5):483-488.  (PubMed)

38.  Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002;23(9):1491-1496.  (PubMed)

39.  Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95(15):1158-1164.  (PubMed)

40.  Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol. 1997;146(4):294-306.  (PubMed)

41.  Xu WH, Zheng W, Xiang YB, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ. 2004;328(7451):1285.  (PubMed)

42.  Murray MJ, Meyer WR, Lessey BA, Oi RH, DeWire RE, Fritz MA. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. Menopause. 2003;10(5):456-464.  (PubMed)

43.  Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev. 2003;61(4):117-131.  (PubMed)

44.   Steiner C, Arnould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr. 2008;99 E Suppl 1:ES78-108. (PubMed)

45.  Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2004;13(4):644-648.  (PubMed)

46.  Jenkins DJ, Kendall CW, D'Costa MA, et al. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol. 2003;169(2):507-511.  (PubMed)

47.  Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol. 2001;165(1):294-300.  (PubMed)

48.  Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer. 2004;48(2):160-170.  (PubMed)

49.  Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2003;47(2):111-117.  (PubMed)

50.  Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 2004;64(3):510-515.  (PubMed)

51.  Pendleton JM, Tan WW, Anai S, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008;8:132.  (PubMed)

52.  Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int. 2006;89(4):1121-1134.  (PubMed)

53.   Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr. 2009;89(4):1155-1163. (PubMed)

54.  Goetzl MA, Van Veldhuizen PJ, Thrasher JB. Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis. 2007;10(3):216-223.  (PubMed)

55.  Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr. 2003;78(3 Suppl):593S-609S.  (PubMed)

56.  Chiechi LM, Secreto G, D'Amore M, et al. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Maturitas. 2002;42(4):295-300.  (PubMed)

57.  Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause. 2001;8(5):384-392.  (PubMed)

58.  Arjmandi BH, Khalil DA, Smith BJ, et al. Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab. 2003;88(3):1048-1054.  (PubMed)

59.  Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2004;13(9):1000-1007.  (PubMed)

60.  Ye YB, Tang XY, Verbruggen MA, Su YX. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women : a single-blind randomized, placebo-controlled trial. Eur J Nutr. 2006;45(6):327-334.  (PubMed)

61.  Wangen KE, Duncan AM, Merz-Demlow BE, et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 2000;85(9):3043-3048.  (PubMed)

62.  Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000;72(3):844-852.  (PubMed)

63.  Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf). 2003;58(6):704-709.  (PubMed)

64.  Cheong JM, Martin BR, Jackson GS, et al. Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab. 2007;92(2):577-582.  (PubMed)

65.  Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW, Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998;68(6 Suppl):1375S-1379S.  (PubMed)

66.  Arjmandi BH, Lucas EA, Khalil DA, et al. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J. 2005;4(1):8.  (PubMed)

67.  Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA. 2004;292(1):65-74.  (PubMed)

68.  Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial. Eur J Nutr. 2004;43(4):246-257.  (PubMed)

69.  Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause. 2004;11(3):290-298.  (PubMed)

70.  Vitolins M, Anthony M, Lenschik L, Bland DR, Burke GL. Does soy protein and its isoflavones prevent bone loss in peri- and post-menopausal women? Results of a two year randomized clinical trial. J Nutr. 2002;132:582S (abstract).

71.  Newton KM, LaCroix AZ, Levy L, et al. Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas. 2006;55(3):270-277.  (PubMed)

72.  Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial. Menopause. 2004;11(3):246-254.  (PubMed)

73.  Huang HY, Yang HP, Yang HT, Yang TC, Shieh MJ, Huang SY. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem. 2006;17(8):509-517.  (PubMed)

74.  Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F. Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr. 2008;87(3):761-770.  (PubMed)

75.  Kenny AM, Mangano KM, Abourizk RH, et al. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr. 2009;90(1):234-242.  (PubMed)

76.  Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2008;62(2):155-161.  (PubMed)

77.  Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause. 2007;14(5):866-874.  (PubMed)

78.  Vatanparast H, Chilibeck PD. Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype? Nutr Rev. 2007;65(6 Pt 1):294-299.  (PubMed)

79.  Ishimi Y. Soybean isoflavones in bone health. Forum Nutr. 2009;61:104-116.  (PubMed)

80.  Frankenfeld CL, McTiernan A, Thomas WK, et al. Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas. 2006;53(3):315-324.  (PubMed)

81.  White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr. 2000;19(2):242-255.  (PubMed)

82.  Hogervorst E, Sadjimim T, Yesufu A, Kreager P, Rahardjo TB. High tofu intake is associated with worse memory in elderly Indonesian men and women. Dement Geriatr Cogn Disord. 2008;26(1):50-57.  (PubMed)

83.  Duffy R, Wiseman H, File SE. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav. 2003;75(3):721-729.  (PubMed)

84.  File SE, Hartley DE, Elsabagh S, Duffy R, Wiseman H. Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause. 2005;12(2):193-201.  (PubMed)

85.  Kritz-Silverstein D, Von Muhlen D, Barrett-Connor E, Bressel MA. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. Menopause. 2003;10(3):196-202.  (PubMed)

86.  Casini ML, Marelli G, Papaleo E, Ferrari A, D'Ambrosio F, Unfer V. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril. 2006;85(4):972-978.  (PubMed)

87.  Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause. 2007;14(3 Pt 1):489-499.  (PubMed)

88.  Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother. 2007;7(11):1549-1564.  (PubMed)

89.  Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003;290(2):207-214.  (PubMed)

90.  Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-881.  (PubMed)

91.  Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2009;(2):CD004143.  (PubMed)

92.  Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071.  (PubMed)

93.  Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137(10):805-813.  (PubMed)

94.  Howes LG, Howes JB, Knight DC. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas. 2006;55(3):203-211.  (PubMed)

95.  Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms--a systematic review. Maturitas. 2004;47(1):1-9.  (PubMed)

96.  Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol. 2004;104(4):824-836.  (PubMed)

97.  Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause. 2006;13(5):831-839.  (PubMed)

98.  Jou HJ, Wu SC, Chang FW, Ling PY, Chu KS, Wu WH. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet. 2008;102(1):44-49.  (PubMed)

99.  Duffy C, Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt). 2003;12(7):617-631.  (PubMed)

100.  MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005;41(5):708-714.  (PubMed)

101.  Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003;101(6):1213-1220.  (PubMed)

102.  Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20(6):1449-1455.  (PubMed)

103.  Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18(5):1068-1074.  (PubMed)

104.  Fletcher RJ. Food sources of phyto-oestrogens and their precursors in Europe. Br J Nutr. 2003;89 Suppl 1:S39-43.  (PubMed)

105.  Munro IC, Harwood M, Hlywka JJ, et al. Soy isoflavones: a safety review. Nutr Rev. 2003;61(1):1-33.  (PubMed)

106.  Setchell KD, Cole SJ. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J Agric Food Chem. 2003;51(14):4146-4155.  (PubMed)

107.  USDA-Iowa State University Isoflavones Database. United States Department of Agriculture [Web page]. March 15, 2002. Available at: Accessed April 14, 2004.

108.  Chua R, Anderson K, Chen J, Hu M. Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J Altern Complement Med. 2004;10(6):1053-1060.  (PubMed)

109.  Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131(4 Suppl):1362S-1375S.  (PubMed)

110.  Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr. 1998;68(6 Suppl):1453S-1461S.  (PubMed)

111.  Chen Z, Zheng W, Custer LJ, et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer. 1999;33(1):82-87.  (PubMed)

112.  Gleason CE, Carlsson CM, Barnet JH, et al. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age Ageing. 2009;38(1):86-93.  (PubMed)

113.  Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr. 2001;131(11 Suppl):3095S-3108S.  (PubMed)

114.  Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61(13):5045-5050.  (PubMed)

115.  Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr. 2001;131(11):2957-2962.  (PubMed)

116.  Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002;62(9):2474-2477.  (PubMed)

117.  Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA. 2009;302(22):2437-2443.

118.  Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5(10):785-794.  (PubMed)

119.  Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84(11):4017-4024.  (PubMed)

120.  Sartippour MR, Rao JY, Apple S, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer. 2004;49(1):59-65.  (PubMed)

121.  American Academy of Pediatrics Committee on Nutrition. Soy protein-based formulas: recommendations for use in infant feeding. Pediatrics. 1998;101(1 Pt 1):148-153.  (PubMed)

122.  Bhatia J, Greer F. Use of soy protein-based formulas in infant feeding. Pediatrics. 2008;121(5):1062-1068.  (PubMed)

123.  Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr. 1998;68(6 Suppl):1453S-1461S.  (PubMed)

124.  Mendez MA, Anthony MS, Arab L. Soy-based formulae and infant growth and development: a review. J Nutr. 2002;132(8):2127-2130.  (PubMed)

125.  Badger TM, Gilchrist JM, Pivik RT, et al. The health implications of soy infant formula. Am J Clin Nutr. 2009;89(5):1668S-1672S.  (PubMed)

126.  Strom BL, Schinnar R, Ziegler EE, et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA. 2001;286(7):807-814.  (PubMed)

127.  US Department of Agriculture, Agricultural Research Service. Study Examines Long-Term Health Effects of Soy Infant Formula. 2004. Available at:

128.  Turck D. Soy protein for infant feeding: what do we know? Curr Opin Clin Nutr Metab Care. 2007;10(3):360-365.  (PubMed)

129.  Divi RL, Chang HC, Doerge DR. Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem Pharmacol. 1997;54(10):1087-1096.  (PubMed)

130.  Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect. 2002;110 Suppl 3:349-353.  (PubMed)

131.  Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid. 2006;16(3):249-258.  (PubMed)

132.  Chorazy PA, Himelhoch S, Hopwood NJ, Greger NG, Postellon DC. Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. Pediatrics. 1995;96(1 Pt 1):148-150.  (PubMed)

133.  Bruce B, Messina M, Spiller GA. Isoflavone supplements do not affect thyroid function in iodine-replete postmenopausal women. J Med Food. 2003;6(4):309-316.  (PubMed)

134.  Persky VW, Turyk ME, Wang L, et al. Effect of soy protein on endogenous hormones in postmenopausal women. Am J Clin Nutr. 2002;75(1):145-153.  (PubMed)

135.  Duncan AM, Merz BE, Xu X, Nagel TC, Phipps WR, Kurzer MS. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab. 1999;84(1):192-197.  (PubMed)

136.  Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999;84(10):3479-3484.  (PubMed)

137.  Dillingham BL, McVeigh BL, Lampe JW, Duncan AM. Soy protein isolates of varied isoflavone content do not influence serum thyroid hormones in healthy young men. Thyroid. 2007;17(2):131-137.  (PubMed)

138.  Natural Medicines Comprehensive Database. Soy. 2004. Available at:

139.  Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother. 2002;36(12):1893-1896.  (PubMed)

140.  Jabbar MA, Larrea J, Shaw RA. Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula. J Am Coll Nutr. 1997;16(3):280-282.  (PubMed)

141.  Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr Pract. 2001;7(3):193-194.  (PubMed)